Hangzhou Panyu Chemical Co.,Ltd--Alprostadil

Products

Alprostadil

Product Name: Alprostadil

Synonyms: Prostaglandin E1; 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid; 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid; PGE1

CAS No.: 745-65-3

EINECS: 212-017-2

Molecular Formula: C₂₀H₃₄O₅

Molecular Weight: 354.48

Molecular Structure:

Transport Information: UN 2811

Description:

Prostaglandin E1 (PGE1) is a prostaglandin.The synthetic variant is known pharmaceutically as alprostadil.It is a drug used in the continuous treatment of erectile dysfunction and has vasodilatory properties. Misoprostol is another synthetic prostaglandin E1 analog used to prevent gastric ulcers when taken on a continuous basis, to treat missed miscarriage, to induce labor, and to induce abortion.

Alprostadil is also used in maintaining a patent ductus arteriosus in newborns. This is primarily useful when the threat of premature closure of the ductus arteriosus exists in an infant with ductal-dependent congenital heart disease, including cyanotic lesions (e.g., pulmonary atresia/stenosis, tricuspid atresia/stenosis, transposition of the great arteries) and acyanotic lesions (e.g., coarctation of the aorta, hypoplastic left heart syndrome, critical aortic stenosis, and interrupted aortic arch).

Application:

PGE1 is the theoretical cyclooxygenase metabolite of dihomo-γ-linolenic acid (DGLA), but it is virtually undetectable in the plasma of normal humans other animals. Its pharmacology includes vasodilation, hypotension, anti-platelet activities.

Patent Disclaimer：

1.Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.

2.Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.

3.R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.